A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
| dc.contributor.author | Manegold, C | |
| dc.contributor.author | van Zandwijk, N | |
| dc.contributor.author | Szczesna, A | |
| dc.contributor.author | Zatloukal, P | |
| dc.contributor.author | Au, J | |
| dc.contributor.author | Blasinska-Morawiec, M | |
| dc.contributor.author | Serwatowski, P | |
| dc.contributor.author | Krzakowski, M | |
| dc.contributor.author | Jassem, J | |
| dc.contributor.author | Tan, E | |
| dc.contributor.author | Benner, R | |
| dc.contributor.author | Ingrosso, A | |
| dc.contributor.author | Meech, S | |
| dc.contributor.author | Readett, D | |
| dc.contributor.author | Thatcher, Nick | |
| dc.date.accessioned | 2012-05-02T12:30:11Z | |
| dc.date.available | 2012-05-02T12:30:11Z | |
| dc.date.issued | 2012-01 | |
| dc.identifier.citation | A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. 2012, 23 (1):72-7 Ann Oncol | en_GB |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.pmid | 21464154 | |
| dc.identifier.doi | 10.1093/annonc/mdr030 | |
| dc.identifier.uri | http://hdl.handle.net/10541/221533 | |
| dc.description.abstract | This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | en_GB |
| dc.title | A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Interdisciplinary Thoracic Oncology, Department of Surgery, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany. | en_GB |
| dc.identifier.journal | Annals of Oncology | en_GB |
| html.description.abstract | This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). |